Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab

Br J Dermatol. 2020 Jul;183(1):176-178. doi: 10.1111/bjd.18877. Epub 2020 Mar 4.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / therapeutic use
  • Antibodies, Monoclonal
  • Complement C5a
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Complement C5a
  • vilobelimab
  • Adalimumab